SiBone (NASDAQ:SIBN) Insider Sells $233,999.96 in Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 11,636 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96. Following the completion of the transaction, the insider directly owned 223,284 shares in the company, valued at $4,490,241.24. This trade represents a 4.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total value of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total value of $55,626.09.

SiBone Trading Down 0.6%

NASDAQ SIBN traded down $0.11 on Wednesday, reaching $19.43. 601,112 shares of the company were exchanged, compared to its average volume of 544,512. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The business’s fifty day moving average price is $17.74 and its 200 day moving average price is $15.40. The stock has a market capitalization of $861.72 million, a P/E ratio of -57.15 and a beta of 0.66. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The business had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. Analysts forecast that SiBone will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SIBN shares. Truist Financial reiterated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. TD Cowen raised their price objective on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. UBS Group boosted their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.17.

Hedge Funds Weigh In On SiBone

Several large investors have recently bought and sold shares of the business. Hussman Strategic Advisors Inc. acquired a new stake in shares of SiBone during the 4th quarter worth approximately $1,656,000. UBS Group AG grew its position in shares of SiBone by 570.2% during the fourth quarter. UBS Group AG now owns 104,731 shares of the company’s stock worth $2,065,000 after acquiring an additional 89,105 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after acquiring an additional 182,465 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of SiBone in the 4th quarter worth about $838,000. Finally, HighMark Wealth Management LLC lifted its position in SiBone by 549.7% in the 4th quarter. HighMark Wealth Management LLC now owns 159,832 shares of the company’s stock valued at $3,152,000 after purchasing an additional 135,232 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.